BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 16928786)

  • 1. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.
    Uno T; Shimizu M; Sugawara K; Tateishi T
    Drug Metab Dispos; 2006 Nov; 34(11):1875-9. PubMed ID: 16928786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
    Shimizu M; Uno T; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 Sep; 62(3):372-6. PubMed ID: 16796706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism.
    Shon JH; Yoon YR; Hong WS; Nguyen PM; Lee SS; Choi YG; Cha IJ; Shin JG
    Clin Pharmacol Ther; 2005 Aug; 78(2):191-201. PubMed ID: 16084853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics.
    Yamada S; Yasui-Furukori N; Akamine Y; Kaneko S; Uno T
    Ther Drug Monit; 2009 Dec; 31(6):764-8. PubMed ID: 19855315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics.
    Yasui-Furukori N; Uno T; Sugawara K; Tateishi T
    Clin Pharmacol Ther; 2005 Jan; 77(1):17-23. PubMed ID: 15637527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of fexofenadine enantiomers in healthy subjects.
    Miura M; Uno T; Tateishi T; Suzuki T
    Chirality; 2007 Mar; 19(3):223-7. PubMed ID: 17230498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-dependent interaction between lopinavir/ritonavir and fexofenadine.
    van Heeswijk RP; Bourbeau M; Campbell P; Seguin I; Chauhan BM; Foster BC; Cameron DW
    J Clin Pharmacol; 2006 Jul; 46(7):758-67. PubMed ID: 16809801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers.
    Russell T; Stoltz M; Weir S
    Clin Pharmacol Ther; 1998 Dec; 64(6):612-21. PubMed ID: 9871426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
    Shimizu M; Uno T; Sugawara K; Tateishi T
    Br J Clin Pharmacol; 2006 May; 61(5):538-44. PubMed ID: 16669847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal interaction between itraconazole and cimetidine.
    Karyekar CS; Eddington ND; Briglia A; Gubbins PO; Dowling TC
    J Clin Pharmacol; 2004 Aug; 44(8):919-27. PubMed ID: 15286096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction.
    Jin MJ; Han HK
    J Food Sci; 2010 Apr; 75(3):H93-6. PubMed ID: 20492299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS.
    Yamazaki A; Kumagai Y; Yamane N; Tozuka Z; Sugiyama Y; Fujita T; Yokota S; Maeda M
    J Clin Pharm Ther; 2010 Apr; 35(2):169-75. PubMed ID: 20456735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of fexofenadine enantiomers.
    Miura M; Uno T
    Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):69-74. PubMed ID: 19947891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of rifampin administration on the disposition of fexofenadine.
    Hamman MA; Bruce MA; Haehner-Daniels BD; Hall SD
    Clin Pharmacol Ther; 2001 Mar; 69(3):114-21. PubMed ID: 11240975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of St John's wort on the pharmacokinetics of fexofenadine.
    Wang Z; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2002 Jun; 71(6):414-20. PubMed ID: 12087344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
    Varis T; Kivistö KT; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters.
    Yasui-Furukori N; Saito M; Niioka T; Inoue Y; Sato Y; Kaneko S
    Ther Drug Monit; 2007 Feb; 29(1):45-8. PubMed ID: 17304149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides.
    Dresser GK; Kim RB; Bailey DG
    Clin Pharmacol Ther; 2005 Mar; 77(3):170-7. PubMed ID: 15735611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates.
    Lemma GL; Wang Z; Hamman MA; Zaheer NA; Gorski JC; Hall SD
    Clin Pharmacol Ther; 2006 Mar; 79(3):218-30. PubMed ID: 16513446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.